- Home
- CARM vs CYTH Comparison
CARM vs CYTH Comparison
Compare CARM & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- CYTH
- Stock Information
- Founded
- CARM 2016
- CYTH 1990
- Country
- CARM United States
- CYTH United States
- Employees
- CARM N/A
- CYTH N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- CYTH Health Care
- Exchange
- CARM Nasdaq
- CYTH Nasdaq
- Market Cap
- CARM 17.4M
- CYTH 20.4M
- IPO Year
- CARM N/A
- CYTH N/A
- Fundamental
- Price
- CARM $0.44
- CYTH $0.80
- Analyst Decision
- CARM Hold
- CYTH Buy
- Analyst Count
- CARM 5
- CYTH 3
- Target Price
- CARM $4.57
- CYTH $0.95
- AVG Volume (30 Days)
- CARM 277.1K
- CYTH 55.3K
- Earning Date
- CARM 11-07-2024
- CYTH 11-14-2024
- Dividend Yield
- CARM N/A
- CYTH N/A
- EPS Growth
- CARM N/A
- CYTH N/A
- EPS
- CARM N/A
- CYTH N/A
- Revenue
- CARM $20,268,000.00
- CYTH $870,725.00
- Revenue This Year
- CARM $46.34
- CYTH N/A
- Revenue Next Year
- CARM N/A
- CYTH $24.49
- P/E Ratio
- CARM N/A
- CYTH N/A
- Revenue Growth
- CARM 41.13
- CYTH N/A
- 52 Week Low
- CARM $0.38
- CYTH $0.55
- 52 Week High
- CARM $2.77
- CYTH $2.12
- Technical
- Relative Strength Index (RSI)
- CARM 37.99
- CYTH 67.47
- Support Level
- CARM $0.42
- CYTH $0.55
- Resistance Level
- CARM $0.48
- CYTH $0.72
- Average True Range (ATR)
- CARM 0.06
- CYTH 0.07
- MACD
- CARM 0.01
- CYTH 0.02
- Stochastic Oscillator
- CARM 18.67
- CYTH 92.59
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.